While biomarkers are integral to the identification and validation of disease treatment methods, there is a disconnect between existing validation approaches and their applications in commercialisation.

Proteins in the brain and plasma of individuals with sporadic Alzheimer’s disease are altered, supporting the hypothesis that plasma biomarkers have utility in predicting early onset in cognitively unimpaired populations.

In modern healthcare, biomarkers are an integral part of approaches to monitoring patient health and condition, providing researchers with a means of predicting treatment response. But what was the first biomarker to be discovered?

The high sensitivity and specificity of ddPCR assays makes the approach well-suited for screening diseases and diagnosing cancer subtypes. Here, we explore some of the ways in which medical researchers are using the technology to pioneer detection of circulating biomarkers for liquid biopsies.

Blood is a rich source for biomarker development, and CTCs are increasingly proving themselves to be valuable in cancer prognosis and treatment prediction.

On-Demand Webinar featuring Dr Mo Jain, Founder & CEO of Sapient

This webinar shares how next-generation, high throughput mass spectrometry, advanced data analysis, and population-scale data are being leveraged for robust discovery of biomarkers that can be used to align patients, disease biology, and therapeutic interventions for clinical trials.

Precision medicine involves tailoring a therapeutic to a patient’s disease: developing precision therapies require an accurate identification of therapeutic targets from available data.

On-Demand Webinar featuring Marina Cretich, Senior Researcher of the National Research Council of Italy at SCITEC-CNR

While the complexities associated with identifying tumour state and coordinating an effective immunotherapeutic response are many, pioneering healthcare providers are rising to the challenge.

Biomarkers in psychiatry may have the potential to overcome the challenges associated with complications such as depression, bipolar disorder, and generalised anxiety.

ICIs – immune checkpoint inhibitors – have changed the landscape of therapeutic treatment for cancer and improved survival rates for patients with advanced malignancies. However, the wide variability in clinical response is a significant limitation to treatment.

An understanding of the complex pathologies involved in patients with neurodegenerative diseases is integral to the identification of biomarkers and potential treatment methods for individuals who suffer from Alzheimer’s, Parkinson’s, and ALS. Here, we look at the development of dedicated biomarker strategies for helping to combat neurodegeneration.